Warning: The NCBI web site requires JavaScript to function. more...
Growth inhibition of androgen-responsive prostate cancer cells with brefeldin A targeting cell cycle and androgen receptor.
Rajamahanty S, Alonzo C, Aynehchi S, Choudhury M, Konno S.
J Biomed Sci. 2010 Jan 26;17:5.
Related citations
Attenuation of androgenic regulation by brefeldin A in androgen-responsive prostate cancer cells.
Alexander B, Fishman AI, Green D, Choudhury MS, Konno S.
Urol Oncol. 2011 Jul 25. [Epub ahead of print]
Involvement of p27Kip1 in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells.
Tsihlias J, Zhang W, Bhattacharya N, Flanagan M, Klotz L, Slingerland J.
Oncogene. 2000 Feb 3;19(5):670-9.
The effects of brefeldin A (BFA) on cell cycle progression involving the modulation of the retinoblastoma protein (pRB) in PC-3 prostate cancer cells.
Mordente JA, Konno S, Chen Y, Wu JM, Tazaki H, Mallouh C.
J Urol. 1998 Jan;159(1):275-9.
Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.
Kokontis JM, Hay N, Liao S.
Mol Endocrinol. 1998 Jul;12(7):941-53.
Galbanic acid decreases androgen receptor abundance and signaling and induces G1 arrest in prostate cancer cells.
Zhang Y, Kim KH, Zhang W, Guo Y, Kim SH, Lü J.
Int J Cancer. 2012 Jan 1;130(1):200-12. doi: 10.1002/ijc.25993. Epub 2011 May 9.
Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor.
Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, Brown TJ.
Mol Cell Endocrinol. 1997 Jan 3;126(1):59-73.
Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells.
Yeap BB, Krueger RG, Leedman PJ.
Endocrinology. 1999 Jul;140(7):3282-91.
Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ, Grigoryev DN, Nnane IP, Liu Y, Ling YZ, Brodie AM.
Cancer Res. 2000 Dec 1;60(23):6630-40.
Brefeldin A-induced apoptosis in prostatic cancer DU-145 cells: a possible p53-independent death pathway.
Chapman JR, Tazaki H, Mallouh C, Konno S.
BJU Int. 1999 Apr;83(6):703-8.
Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells.
Ye D, Mendelsohn J, Fan Z.
Clin Cancer Res. 1999 Aug;5(8):2171-7.
A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
Recchia AG, Musti AM, Lanzino M, Panno ML, Turano E, Zumpano R, Belfiore A, Andò S, Maggiolini M.
Int J Biochem Cell Biol. 2009 Mar;41(3):603-14. Epub 2008 Jul 23.
Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.
Xu Y, Chen SY, Ross KN, Balk SP.
Cancer Res. 2006 Aug 1;66(15):7783-92.
Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA, Visakorpi T.
Cancer Res. 2009 Oct 15;69(20):8141-9. Epub 2009 Oct 6.
Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.
Cancer Res. 2004 Oct 1;64(19):7156-68.
Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines.
Hsieh TC, Wu JM.
Exp Cell Res. 1999 May 25;249(1):109-15.
TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML, Partin JV, Bruckheimer EM, Strup SE, Kyprianou N.
Prostate. 2008 Feb 15;68(3):287-95.
Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
Jackson KM, Frazier MC, Harris WB.
Anticancer Res. 2007 May-Jun;27(3B):1483-8.
Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S, Agoulnik IU, Weigel NL.
Prostate. 2005 Sep 1;64(4):362-72.
Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer.
van der Poel HG.
Eur Urol. 2005 Dec;48(6):1051-8. Epub 2005 Oct 14.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on